ZYME Summary

  1. NYSE
  2. >
  3. ZYME
TickerZYME
DescriptionZYMEWORKS INC
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks' second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
ExchangeNYSE
TypeStock
SectorHealthcare
Employees354
Next Earnings DateFebruary 23rd, 2022
IV91.15673%
IV Percentile67th
IV Rank24.12%
IV Skew2.406141
IV Skew Percentile67th
IV Skew SentimentBearish
Option Volume81
Volume482,953
Price$18.49
Previous Close$20.24
52-Week High$59.03
52-Week Low$17.71
50-Day Moving Avg.$21.68
200-Day Moving Avg.$30.10
10-Day Avg. Volume1,120,669
20-Day Avg. Volume852,289
30-Day Avg. Volume752,530
3-Month Avg. Volume688,462
EPS-$4.39
Outstanding Shares46,553,964
Market Capitalization$942,252,200
CurrencyUSD
UpdatedDecember 3rd, 2021